1)日本頭痛学会,国際頭痛分類委員会(訳):国際頭痛分類第3版beta版,医学書院,pp 31-205, 2014
2)日本神経学会,日本頭痛学会(監):慢性頭痛の診療ガイドライン 2013,医学書院,pp 2-343, 2013
3)Evers S, et al:Placebo efficacy in childhood and adolescence migraine;An analysis of double-blind and placebo-controlled studies. Cephalalgia 29:436-444, 2009
4)Fujita M, et al:Oral sumatriptan for migraine in children and adolescents;A randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia 34:365-375, 2014
5)Ahonen K, et al:A randomized trial of rizatriptan in migraine attacks in children. Neurology 67:1135-1140, 2006
6)Fraser IP, et al:Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache 52:625-635, 2012
7)Hewitt DJ, et al:Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs. Headache 53:104-117, 2012
8)大澤真木子,林 雅晴:適応外使用薬剤の解決に向けて今我々ができること発達障害に対する適応外使用薬剤と今後の適応承認獲得への実践を探る.脳と発達46:136-139, 2014
9)Lindkvist J, et al:Evolution of paediatric off-label use after new significant medicines become available for adults;A study on triptans in Finnish children 1994-2007. Br J Clin Pharmacol 71:929-935, 2011